个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Song-Tao Xu[a] ; Jun-Jie Xi[a] ; Wen-Zhao Zhong[b] ; Wei-Min Mao[c] ; Lin Wu[d] ; Yi Shen[e] ; Yong-Yu Liu[f] ; Chun Chen[g] ; Ying Cheng[h] ; Lin Xu[i] ; Jun Wang[j] ; Ke Fei[k] ; Xiao-Fei Li[l] ; Jian Li[m] ; Cheng Huang[n] ; Zhi-Dong Liu[o] ; Shun Xu[p] ; Ke-Neng Chen[q] ; Shi-Dong Xu[r] ; Lun-Xu Liu[s] ; Ping Yu[t] ; Bu-Hai Wang[u] ; Hai-Tao Ma[v] ; Hong-Hong Yan[b] ; Xue-Ning Yang[b] ; Yong-Xing Zhang[a] ; Jia-Cheng Yin[a] ; Qun Wang[a] ; Yi-Long Wu[b,*a] ;
机构： [a]Zhongshan Hospital, Fudan University, Shanghai, China [b]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou,China [c]Zhejiang Cancer Hospital, Hangzhou, China [d]Hunan Cancer Hospital, Changsha, China [e]The Affiliated Hospital of Medical College, Qingdao University, Qingdao, China [f]Liaoning Cancer Hospital, Shenyang, China [g]Fujian Medical University Union Hospital, Fuzhou, China [h]Jilin Provincial Cancer Hospital, Changchun, China [i]Jiangsu Cancer Hospital, Nanjing, China [j]The People’s Hospital of Peking University, Beijing, China [k]Shanghai Pulmonary Hospital, Shanghai, China [l]Tangdu Hospital, Xi’an, China [m]Peking University First Hospital, Beijing, China [n]Fujian Cancer Hospital, Fuzhou, China [o]Beijing Chest Hospital, Beijing, China [p]The First Hospital of China,Medical University, Shenyang, China [q]Beijing Cancer Hospital, Beijing, China [r]The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China [s]West China,Hospital of Sichuan University, Chengdu, China [t]Sichuan Cancer Hospital, Chengdu, China [u]The Northern Jiangsu People’s Hospital, Yangzhou, China [v]The First Affiliated Hospital of Suzhou University, Suzhou, China
出处：
DOI： 10.1016/j.jtho.2018.11.020
ISSN：

关键词： NSCLC EGFR tyrosine kinase inhibitor gefitinib adjuvant chemotherapy

摘要：
Introduction: Adjuvant gefitinib therapy prolonged disease-free survival in patients with resected early-stage EGFR-mutation positive NSCLC in the ADJUVANT study (CTONG 1104). However, treatment failure patterns after gefitinib therapy are less well characterized. Methods: Overall, 222 stage N1-N2, EGFR-mutant NSCLC patients received gefitinib or vinorelbine plus cisplatin (VP) treatment. Tumor recurrences or metastases occurring during follow-up were defined as treatment failure; sites and data of first treatment failure were recorded. A post hoc analysis of treatment failure patterns which was estimated by Kaplan-Meier and hazard rate curves in modified intention-to-treat patients was conducted. Results: There were 114 recurrences and 10 deaths before recurrence across 124 progression events. Spatial distribution analysis showed that the first metastasis site was most frequently the central nervous system in the gefitinib group (29 of 106 [27.4%]), extracranial metastases were most frequent in the VP group (32 of 87 [36.8%]). Temporal distribution analysis showed lower tumor recurrence with gefitinib than with VP 0 to 21 months post-surgery. However, recurrence with gefitinib showed a constant rate of increase 12 months post-surgery. The first peak of extracranial metastasis appeared during 9 to 15 months with VP and 24 to 30 months with gefitinib. The highest peak for central nervous system metastases post-surgery occurred after 12 to 18 months with VP and 24 to 36 months with gefitinib. Conclusions: Adjuvant gefitinib showed advantages over VP chemotherapy in treatment failure patterns especially in extracranial metastasis. Adjuvant tyrosine kinas inhibitors may be considered as a treatment option in resected stage N1-N2 EGFR-mutant NSCLC but longer duration should be explored. (C) 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

基金：
Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine [2012A061400006]; National Health and Family Planning Commission of China [201402031]; Guangzhou Science and Technology Bureau [2011Y2-00014, 2014Y2-00545]; AstraZeneca ChinaAstraZeneca; Chinese Thoracic Oncology Group
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 2 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2019]版：
Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者机构： [a]Zhongshan Hospital, Fudan University, Shanghai, China
共同第一作者：
通讯作者：
通讯机构： [b]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou,China [*a]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, 106 Second Zhongshan Road, Guangzhou 510080, China
推荐引用方式(GB/T 7714)：
Song-Tao Xu,Jun-Jie Xi,Wen-Zhao Zhong,et al.The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)[J].JOURNAL OF THORACIC ONCOLOGY.2019,14(3):503-512.doi:10.1016/j.jtho.2018.11.020.
APA：
Song-Tao Xu,Jun-Jie Xi,Wen-Zhao Zhong,Wei-Min Mao,Lin Wu...&Yi-Long Wu.(2019).The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104).JOURNAL OF THORACIC ONCOLOGY,14,(3)
MLA：
Song-Tao Xu,et al."The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)".JOURNAL OF THORACIC ONCOLOGY 14..3(2019):503-512

相关文献

[1]Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC. [2]Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC. [3]表皮生长因子受体酪氨酸激酶抑制剂Gefitinib对鼻咽癌荷瘤裸鼠移植瘤生长作用的实验研究 [4]First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 [5]Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation [6]Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC. [7]Identification of tumor microenvironment-based genes associated with acquired resistance to EGFR Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. [8]A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. [9]Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged >= 75 Years: Subgroup Analysis of LUX-Lung 7 [10]Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)

资源点击量：43370 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号